- Home
- PAXS vs MRVI Comparison
PAXS vs MRVI Comparison
Compare PAXS & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- MRVI
- Stock Information
- Founded
- PAXS 2021
- MRVI 2020
- Country
- PAXS United States
- MRVI United States
- Employees
- PAXS N/A
- MRVI N/A
- Industry
- PAXS Investment Managers
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- PAXS Finance
- MRVI Health Care
- Exchange
- PAXS Nasdaq
- MRVI Nasdaq
- Market Cap
- PAXS 722.0M
- MRVI 809.2M
- IPO Year
- PAXS N/A
- MRVI 2020
- Fundamental
- Price
- PAXS $15.58
- MRVI $4.77
- Analyst Decision
- PAXS
- MRVI Buy
- Analyst Count
- PAXS 0
- MRVI 10
- Target Price
- PAXS N/A
- MRVI $10.28
- AVG Volume (30 Days)
- PAXS 195.0K
- MRVI 1.8M
- Earning Date
- PAXS 01-01-0001
- MRVI 02-25-2025
- Dividend Yield
- PAXS 11.72%
- MRVI N/A
- EPS Growth
- PAXS N/A
- MRVI N/A
- EPS
- PAXS N/A
- MRVI N/A
- Revenue
- PAXS N/A
- MRVI $276,920,000.00
- Revenue This Year
- PAXS N/A
- MRVI N/A
- Revenue Next Year
- PAXS N/A
- MRVI $2.25
- P/E Ratio
- PAXS N/A
- MRVI N/A
- Revenue Growth
- PAXS N/A
- MRVI N/A
- 52 Week Low
- PAXS $12.57
- MRVI $4.28
- 52 Week High
- PAXS $15.93
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- PAXS 46.66
- MRVI 39.85
- Support Level
- PAXS $15.29
- MRVI $4.38
- Resistance Level
- PAXS $15.93
- MRVI $6.21
- Average True Range (ATR)
- PAXS 0.25
- MRVI 0.39
- MACD
- PAXS 0.02
- MRVI -0.09
- Stochastic Oscillator
- PAXS 59.77
- MRVI 21.31
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.